Based on the data obtained by us and the above-mentioned studies, we suggest that stimulation of mitochondrial pathway-derived caspase-9 and resulting effector caspase activity is required for the efficient caspase-8 activation in the cisplatin/LA-12 and TRAIL combination-treated prostate cancer cells. The gene discussed is CASP8; the disease is prostate carcinoma.